Michael S. Gordon

Michael S. Gordon, D.P.A

Michael S. Gordon, D.P.A
Michael S. Gordon, D.P.A
Senior Research Scientist

D.P.A., Public Administration, University of Baltimore
mgordon@friendsresearch.org
Phone: 410-837-3977 ext. 251
Fax: 410-752-4218
Research Interests

Dr. Gordon has expertise and experience in developing, implementing, and evaluating innovative substance abuse treatment interventions for criminal justice populations (prisoners, parolees, probationers) with histories of opioid addiction. In addition, he conducts HIV and technology-based research with criminal justice populations. Dr. Gordon has been Principal Investigator or Co-Investigator on six major studies that have contributed to the field of substance abuse, HIV and criminal justice: (1) methadone maintenance for prisoners, (2) buprenorphine for prisoners, (3) long-acting naltrexone for prisoners, (4) long-acting naltrexone for probationers and parolees; (5) rapid HIV testing for criminal justice populations, and 6) criminal justice drug abuse treatment studies.

Dr. Gordon is a two-time recipient of the National Institutes of Health (NIH) Clinical Research Loan Repayment Program Award. Furthermore, he has been the recipient of three travel awards, two from the National Institute on Drug Abuse (NIDA), and one from the College on Problems of Drug Dependence (CPDD). Dr. Gordon also received the Friends Research Institute 2008 Daniel Mendelsohn/ New Investigator Award. In addition to his work at FRI, since 2011, Dr. Gordon has served as an Adjunct Professor in the School of Humanities and Social Sciences at Stevenson University.

Selected Publications
Crable E, Blue T, Mackenzie M, Rich J, Gordon MS (in press). Effect of case management on HIV outcomes for community corrections population: Results of an 18-month randomized controlled trial. Journal of Acquired Immune Deficiency Syndrome
Gordon MS, Mitchell SG, Blue TR, Vocci FJ, Fishman MJ, Murphy SM, Couvillion K, Maher K, Ryan D, Wenzel K, Danner ML, Jarvis DK (in press). A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail. Journal of Substance Abuse Treatment
Schwartz RP, Mitchell MM, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Gordon MS, Jaffe JH (in press). Pharmacotherapy for Opioid Addiction in Community Corrections International Review of Psychiatry 2018 Dec 6:1-19. doi: 10.1080/09540261.2018.1524373. [Epub ahead of print] PMID: 30522370.
Blue, T. R., Fletcher, J. B., Monico, L. B., Gordon, M. S., Schwartz, R. P., & Mitchell, S. G. (2023). Jail and treatment staff attitudes regarding MOUDs before and after an implementation intervention. Journal of Offender Rehabilitation, 62 (7), 411-426. https://doi.org/10.1080/10509674.2023.2246446.
Carswell, S.B., Gordon, M.S., Gryczynski, J., Horodyski, A.M., Ferguson, K.N., Maher, K.M., & Vocci, F.J. (2023). The daily progress system – a recovery support tool to improve engagement and retention in outpatient substance use treatment. Journal of Substance Use, 1-6.DOI: 10.1080/14659891.2023.2261036.
Farago F, Smith L, Cloud V, Gordon M, & Taxman F (2023). Pilot study: An exploration of Medication Assisted-Treatment (MAT) for indigenous Americans within tribal healing to wellness courts. Journal of Qualitive Criminal Justice. https://doi.org/10.21428/88de04a1.d21bf9fc.
Smith, L. R., Faragó, F., Blue, T., Witte, J. C., Gordon, M. S., & Taxman, F. S. (2023). Viewing Then Doing?: Problem-Solving Court Coordinators’ Perceptions of Medications for Opioid Use Disorders from a Nationally Representative Survey in the United States. Subst Use Misuse, 58 (13), 1780-1788. https://doi.org/10.1080/10826084.2023.2247076.
Carswell, S.B., Gordon MS, Gryczynski J, Taxman FS, Schadegg M, Ferguson KN & Maher K (2022). Continuing care application for probationers and parolees with substance use disorders. Journal of Drug Education, 51 (1-2), 32-48, DOI 10.1177/00472379221111.
Ludwig, A., Monico, L. B., Blue, T., Gordon, M. S., Schwartz, R. P., & Mitchell, S. G. (2022). Development and use of a checklist for the implementation of medication for opioid use disorder in jails. Implementation Research and Practice, 3 , 26334895221101214. Doi: 10.1177/26334895221101214.
Crable, E. L., Blue, T. R., McKenzie, M., Rich, J. D., & Gordon, M. S. (2021). Effect of case management on HIV outcomes for community corrections population: Results of an 18-month randomized controlled trial. JAIDS Journal of Acquired Immune Deficiency Syndromes, 87 (1), 755-762.
Gordon, M. S., Mitchell, S. G., Blue, T. R., Vocci, F. J., Fishman, M. J., Murphy, S. M., Couvillion, K., Maher, K., Ryan, D., Wenzel, K., Danner, M. L., & Jarvis, D. K. (2021). A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. Journal of Substance Abuse Treatment, 128, 108241.
Gordon MS, Mitchell SG, Blue TR, Vocci FJ, Fishman MJ, Murphy SM, CouvillionK, Maher K, Ryan D, Wenzel K, Danner ML, Jarvis DK (2020). A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. Journal of Substance Abuse Treatment 108241.
Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, Woody GE, Polsky D (2020). Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. Addiction Science & Clinical Practice 15, 1-11.
Blue TR, Gordon MS, Schwartz RP, Couvillion K, Vocci FJ, Fitzgerald TT, O’Grady KE (2019). Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine Addiction Science & Clinical Practice 14(1):45. doi: 10.1186/s13722-019-0172-2. PMID:31787108.
Gordon MS, Vocci FJ, Taxman F, Fishman M, Sharma B, Blue TR, O’Grady KE (2019). A Randomized Controlled Trial of Buprenorphine for Probationers and Parolees: Bridging the Gap into Treatment Contemporary Clinical Trials 79:21-27. doi: 10.1016/j.cct.2019.02.009. Epub 2019 Feb 20. PMID: 30797042.
Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA (2019). Approaches for Creating Comparable Measures of Alcohol use Symptoms: Harmonization with Eight Studies of Criminal Justice populations Drug and Alcohol Dependence 194:59-68. doi: 10.1016/j.drugalcdep.2018.10.003. Epub 2018 Oct 23. PMID: 30412898.
Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D (2019). Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap Journal of Substance Abuse Treatment 103:1-8. doi: 10.1016/j.jsat.2019.05.002. Epub 2019 May 9. PMID: 31229187.
Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O’Brien, CP, Shroff M, Friedmann PD (2019). Incidence of Future Arrests in Adults involved in the Criminal Justice System with Opioid Use Disorder receiving Extended Release Naltrexone compared to Treatment as Usual Drug and Alcohol Dependence 194, 482-486 doi: 10.1016/j.drugalcdep.2018.10.035. Epub 2018 Dec 3. PMID:30522048.
Carswell, S.B., Gordon MS, Gryczynski J, and Tangires S (2018). The daily progress system: A proof of concept pilot study of a recovery support technology tool for outpatient substance abuse treatment The American Journal of Drug and Alcohol Abuse Published online: 30 May 2018.
Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, and O’Brien CP (2018). Personal control over decisions to participate in research by persons with histories of both substance use disorders and criminal justice supervision Journal of Empirical Research on Human Research Ethics 13(2):160-172. doi: 10.1177/1556264618755243. Epub 2018 Feb 20.PMID: 29460668.
Friedmann PD, Wilson D, Nunes EV, Hoskinson Jr R, Lee JD, Gordon MS, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O’Brien CP (2018). Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? Journal of Substance Abuse Treatment Available at: http://dx.doi.org/10.1016/j.jsat.2017.01.018.
Gordon MS, Blue TR, Couvillion K, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ (2018). Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes Drug and Alcohol Dependence 188:232-238. doi: 10.1016/j.drugalcdep.2018.04.010. Epub 2018 May 12. PMID: 29783095.
Gordon MS, Crable EL, Carswell, S.B., Leopold J, Hodo-Powell J, McKenzie M, and Rich JD (2018). A randomized controlled trial of intensive case management (Project Bridge) for HIV-infected probationers and parolees AIDS and Behavior 22(3):1030-1038. doi: 10.1007/s10461-017-2016-y. PMID: 29273946.
Nunes EV, Gordon MS, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hi MC, Boney TB, Wilson D, O’Brien CP (2018). Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone . Journal of Substance Abuse Treatment Available at: http://dx.doi.org/10.1016/j.jsat.2017.04.016.
Schwartz RP, Mitchell MM, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Gordon MS, Jaffe JH (2018). Pharmacotherapy for opioid addiction in community corrections International Review of Psychiatry 30(5):117-135. doi: 10.1080/09540261.2018.1524373. Epub 2018 Dec 6. PMID: 30522370.
Soares W, Wilson D, Rathlev N, Lee J, Gordon MS, Nunes E, O’Brien CP, Friedmann P (2018). Healthcare Utilization in Adults with Opioid Dependence receiving Extended Release Naltrexone compared to Treatment as Usual Journal of Substance Abuse Treatment Available at: http://dx.doi.org /10.1016/j.jsat.2017.05.009.
Allen A, Chen D, Bonnie RJ, Koa TM, Surratt CE, Lee JD, Friedmann P, Gordon MS, McDonald R, Murphy S, Boney T, Nunes E, O’Brien CP (2017). Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision Journal of Substance Abuse Treatment 81, 66–72.
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM (2017). Cohort profile: seek, test, treat and retain United States criminal justice cohort Substance Abuse Treatment, Prevention, and Policy 12(1):24. doi: 10.1186/s13011-017-0107-4. PMID:28511680.
Gordon MS (2017). Television interview with Investigative Reporter Barry Sims of WBAL-TV Channel 11. Long-acting naltrexone for prisoners
Gordon MS, Carswell, S.B., Peters EN, Tangires S, Kinlock TW, Vocci FJ, and Restivo L (2017). Avatar assisted therapy: A novel technology-based Intervention to treat substance use disorders In Pam Lassiter (ed.), Annual Review of Addictions and Offender Counseling: Best Practices III (p 97 - 114). Eugene, OR: Wipf & Stock Publishers.
Gordon MS, Carswell, S.B., Schadegg M, Mangen K, Merkel K, Tangires S, Vocci FJ (2017). Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disorders American Journal of Drug and Alcohol Abuse 43(5):518-524. doi: 10.1080/00952990.2017.1280816.
Gordon MS, Fitzgerald TT (2017). Television interview with Maryland Department of Public Safety Reporter Gerard Shields. Long-acting naltrexone for prisoners
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ (2017). A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release Drug and Alcohol Dependence 172:34-42. doi: 10.1016/j.drugalcdep.2016.11.037. Epub 2017 Jan 11. PMID: 28107680.
Gordon MS, Vocci FJ, Fitzgerald TT, O’Grady KE, O’Brien CP (2017). Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment Contemporary Clinical Trials 53:130-136. doi: 10.1016/j.cct.2016.12.015. PMID:28011389.
Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA (2017). Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium AIDS and Behavior. doi 10.1007/s10461-017-1722-9. PMID:28188460.
Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM (2017). Co-calibration of two self-reported measures of adherence to antiretroviral therapy AIDS Care 29(4):464-468. doi: 10.1080/09540121.2016.1263721.
Zaller N, Gordon MS, Bazerman L, Kuo I, Beckwith C (2017). Individuals under community supervision in Baltimore, MD Journal of Correctional Healthcare 23(3), 305-312.
Gordon MS, Carswell, S.B., Wilson M, Kinlock TW, Restivo LL, McKenzie M, Rich JD, (2016). Factors Associated With Receiving Rapid HIV Testing Among Individuals on Probation or Parole Journal of Correctional Health Care 22(4):290-299. PMID: 27742854.
Kinlock TW, and Gordon MS (2016). Heroin and Other Opiates. In Henry H. Brownstein (ed.) The Handbook of Drugs and Society (pp. 72-89). West Sussex, UK: John Wiley & Sons, Inc.
Mitchell SG, Willett J, Monico LB, James A, Rudes DS, Viglioni J, Schwartz RP, Gordon MS, Friedmann PD (2016). Community Correctional Agents’ Views of Medication-Assisted Treatment: Examining their Influence on Treatment Referrals and Community Supervision Practices. Substance Abuse 37(1):127-33. doi: 10.1080/08897077.2015.1129389. PMID: 26860334. PMCID: PMC4823810.
Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, Sudec LJ, O’Grady KE, Vocci FJ, Shabazz H (2015). Buprenorphine Treatment for Probationers and Parolees Substance Abuse 36(2):217-25. doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4. PMID: 24701967.
Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A, Silverman B (2015). A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners Journal of Substance Abuse Treatment 59:52-8. doi: 10.1016/j.jsat.2015.07.005. Epub 2015 Jul 18. PMID: 26299956.
Kinlock TW and Gordon MS (2015). Pharmacotherapy for Incarcerated Individuals with Histories of Heroin Addiction. In Ayman M. Fareed (ed.), Heroin Addiction: Prevalence, Treatment Approaches and Health Consequences (pp. 127-142). Hauppauge, NY: Nova Science Publishers, Inc.
Lee JD, Friedmann PD, Boney TY, Hoskinson RA Jr, McDonald R, Gordon MS, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O’Brien CP (2015). Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial Contemporary Clinical Trials 41:110-7.
Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O’Grady KE, Jaffe JH (2015). Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug and Alcohol Dependence 156:133-8. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7. PMID: 26409751.
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ (2014). A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry Drug and Alcohol Dependence 142, 33-40. doi: 10.1016/j.drugalcdep.2014.05.011. Epub 2014 Jun 2. PMID: 24962326.
Friedmann PD, Ducharme LJ, Welsh W, Frisman L, Knight K, Kinlock T, Mitchell SG, Hall E, Urbine T, Gordon MS, Abdel-Salam S, O’Connell D, Albizu-Garcia C, Knudsen H, Duval J, Fenster J; Jennifer Pankow for the CJ-DATS MATICCE Workgroup (2013). A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol Health Justice 19; 1(6). doi: 10.1186/2194-7899-1-6. PMID: 25309847. PMCID: PMC4193542.
Gordon MS, Kinlock TW, Couvillion KA, Schwartz RP, Wilson ME, O’Grady KE (2013). Gender differences among prisoners with pre-incarceration heroin dependence participating in a randomized clinical trial of buprenorphine treatment. Journal of Offender Rehabilitation 52(5), 376-391.
Gordon MS, Kinlock TW, McKenzie M, Rich JD, Wilson ME (2013). Rapid HIV testing for individuals on probation/parole: Outcomes of an intervention trial. AIDS and Behavior 17(6), 2022-2030.
Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, O’Grady KE (2013). The Severity, Frequency, and Variety of Crime in Heroin-Dependent Prisoners Enrolled in a Buprenorphine Clinical Trial Prison Journal 93(4):390-410.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE (2013). Individual Patient and Program Factors Related to Prison and Community Treatment Completion in Prison-Initiated Methadone Maintenance Treatment.  Journal of Offender Rehabilitation 52(8):509-528.
Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PDNunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O’Brien CP (2012). A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers Substance Abuse 33 (1), 48-59. [PMCID: PMC3365863].
Friedmann PD, Hoskinson R, Gordon MS, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O’Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions Substance Abuse 33 (1), 9-18. [PMCID: PMC3295578].
Gordon MS, Kinlock TW, Couvillion K, Schwartz RP, O’Grady KE (2012). A randomized clinical trial of methadone maintenance for prisoners: Prediction of treatment entry and completion in prison Journal of Offender Rehabilitation 51 (4), 222-238.
Gryczynski J, Kinlock TW, Kelly SM, O’Grady KE, Gordon MS, Schwartz RP (2012). Opioid agonist maintenance for probationers: Patient-level predictors of treatment retention, drug use, and crime Substance Abuse 33 (1), 30-39.
Wilson ME, Kinlock TW, Gordon MS, O’Grady KE, Schwartz RP (2012). Post-prison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners The American Journal on Addictions 21 (5), 476-487.
Wilson ME, Kinlock TW, Gordon MS, O’Grady KE, Schwartz RP (2012). Post-prison HIV-risk behaviors in a randomized clinical trial of methadone maintenance treatment American Journal on Addictions 21, 476-487. PMCID: PMC3422766. doi: 10.1111/j.1521-0391.2012.00250.x. PMID: 22882399. PMCID: PMC3422766.
Gordon MS, Kinlock TW, Miller PM (2011). Medication-assisted treatment research with criminal justice populations: challenges of implementation Behavioral Sciences and the Law 29 (6), 829-845. [PMCID: PMC3243915].
Kinlock TW, Gordon MS, Schwartz RP (2011). Incarcerated populations. In P. Ruiz & E. Strain (Eds.) Lowinson & Ruiz’s Substance Abuse: A Comprehensive Textbook (Fifth ed., pp. 881-891). Philadelphia, PA: Lippincott Williams & Wilkins.
Schwartz RP, Mitchell SG, Gordon MS, and Kinlock TW (2011). Pharmocotherapy. In C. Leukefeld, J. Gregrich & T. P. Gullotta (Eds.),  Handbook on Evidence-Based Substance Abuse Treatment Practice in Criminal Justice Settings, Issues in Childrens’ and Families’ Lives 11  (pp. 259-277). New York: Springer Publishing.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT (2010). Developing and implementing a new prison-based buprenorphine treatment program Journal of Offender Rehabilitation 49 (2), 91-109. [PMCID: PMC2868193].
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE (2009). Methadone maintenance for prisoners: Results at twelve-months post-release.  Journal of Substance Abuse Treatment 37, 277-285.
Schwartz RP, Jaffe JH, O’Grady KE, Kinlock TW, Gordon MS, Kelly SM, Wilson ME, Ahmed A (2009). Interim Methadone Treatment: Impact on Arrests.  Drug and Alcohol Dependence 103, 148-154. doi: 10.1016/j.drugalcdep.2009.03.007. Epub 2009 May 14. PMID: 19443133.
Taxman FS and Gordon J (2009). Do fairness and equity matter? An examination of organizational justice among correctional officers in adult prisons Criminal Justice and Behavior 36, 695-711.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE (2008). A randomized clinical trial of methadone maintenance for prisoners: Findings at 6-months post-release Addiction 103 (8), 1333-1342.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE (2008). A study of methadone maintenance for male prisoners: Three-month post-release outcomes Criminal Justice and Behavior 35 (1), 34-47.
Garcia CA, Caraballo Correa G, Hernandez Viver AD, Kinlock TW, Gordon MS, Antron Avila C, Colón Reyes I, Schwartz RP (2007). Buprenorphine-Naloxone Treatment for Pre-release Opioid Dependent Inmates in Puerto Rico Journal of Addiction Medicine 1(6), 126-132. doi: 10.1097/ADM.0b013e31814b8880. PMID: 21768947.
Garcia CA, Correa GC, Hernandez Viver AD, Kinlock TW, Gordon MS, Avila CA, Reyes CI, Schwartz RP (2007). Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico Journal on Addiction Medicine 1(3), 126-132. doi: 10.1097/ADM.0b013e31814b8880. PMID: 21768947.
Gordon MS (2007). Journal of Professional Issues in Criminal Justice The Examination of Correctional Officers' Organizational Commitment 2(2), 191-206.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE, Fitzgerald T, Wilson M (2007). A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release Drug and Alcohol Dependence 91(2-3), 220-227. Epub 2007 Jul 12. PMID: 17628351PMCID: PMC2423344.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE, Fitzgerald T, Wilson M (2007). Examining the Effectiveness of Opioid Agonist Programs for Prisoners at One Month Following Release from Incarceration Drug and Alcohol Dependence 91 (2-3), 220-227.
Gordon MS (2006). Correctional officer control ideology: Implications for understanding a system Criminal Justice Studies 19(3), 225-239.
Kinlock TW, and Gordon MS (2006). Substance abuse treatment: New research In LA Bennett (Ed.), New Topics in Substance Abuse Treatment Hauppauge, NY: Nova Science Publishers, Inc.
Kinlock TW, Schwartz RP, and Gordon MS (2005). The significance of interagency collaboration in developing opioid agonist programs for prisoner Corrections Compendium 30(3), 6-30.
Kinlock TW, Schwartz RP, and Gordon MS (2005). The significance of interagency collaboration in developing opioid agonist programs for prisoners Corrections Compendium 30(3), 28-30.
Battjes RJ, Gordon MS, O’Grady KE, and Kinlock TW (2004). Predicting retention of adolescents in substance abuse treatment Addictive Behavior 29, 1021-1027.
Battjes RJ, Gordon MS, O’Grady KE, Kinlock TW, Katz EC, and Sears EA (2004). Evaluation of a group-based substance abuse treatment program for adolescents Journal of Substance Abuse Treatment 27(2), 123-134.
Gordon MS, Kinlock TW, and Battjes RJ (2004). Correlates of early substance use and crime among adolescents entering outpatient substance abuse treatment American Journal of Drug and Alcohol Abuse 30(1), 21-38.
Kinlock TW, Battjes RJ, and Gordon MS (2004). Factors associated with criminal severity among adolescents entering substance abuse treatment Journal of Drug Issues 34, 293-318.
Kinlock TW, Gordon MS, and Battjes RJ (2004). A Descriptive examination of the pretreatment illegal activities of a nationwide sample of adolescent substance abuse clients Journal of Psychoactive Drugs 36, 1-21.
Battjes RJ, Gordon MS, O’Grady KE, Kinlock TW, and Carswell MA (2003). Factors that predict adolescent motivation for substance abuse treatment Journal of Substance Abuse Treatment 24(3), 221-232.
Battjes RJ, Sears EA, Katz EC, Kinlock TW and Gordon MS (2003). Evaluation of a group-based outpatient adolescent substance abuse treatment program In SJ Stevens & AR Morral (Eds.), Adolescent substance abuse in the United States: Exemplary models from a national evaluation study Binghamton, NY: Hawthorn Press.
Jengeleski JL, and Gordon MS (2003). The Kintock Group, Inc. – Employment Resource Center: A two-year post-release evaluation study Journal of Correctional Education 54(1), 27-30.
Kinlock T, and Gordon MS (2002). Differential case management In D Levinson (Ed.), Encyclopedia of crime and punishment Thousand Oaks, CA: Sage.
Jengeleski JL, and Gordon MS (1999). The Kintock Group, Inc. – Employment Resource Center: An assessment of post release outcomes The Journal of Correctional Education 50(1), 22-26.
Heckert WJ, Jengeleski JL and Gordon MS (1998). Measuring correctional employees’ ideology Pennsylvania Association on Probation, Parole & Correction Journal 58(2), 21-26.